Technical Analysis for SGEN - Seattle Genetics, Inc.
|Grade||Last Price||% Change||Price Change|
SGEN closed up 3.36 percent on Friday, January 18, 2019, on 84 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 5
|See historical SGEN trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 17||Slingshot Bullish||Bullish Swing Setup||3.36%|
|Jan 17||Wide Bands||Range Expansion||3.36%|
|Jan 17||Overbought Stochastic||Strength||3.36%|
|Jan 16||Wide Bands||Range Expansion||2.71%|
|Jan 16||Overbought Stochastic||Strength||2.71%|
|Jan 15||Expansion Breakout||Bullish Swing Setup||2.22%|
|Jan 15||Reversal New Highs Setup||Bullish Swing Setup||2.22%|
|Jan 15||Multiple of Ten Bullish||Other||2.22%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more SGEN news...
|52 Week High||84.37|
|52 Week Low||47.75|
|200-Day Moving Average||64.8966|
|50-Day Moving Average||60.5034|
|20-Day Moving Average||62.968|
|10-Day Moving Average||70.079|
|Average True Range||2.8281|
|Chandelier Exit (Long, 3 ATRs )||65.1557|
|Chandelier Exit (Short, 3 ATRs )||59.9843|
|Upper Bollinger Band||78.0495|
|Lower Bollinger Band||47.8865|
|Percent B (%b)||0.85|
|MACD Signal Line||2.4787|
|Market Cap||10.53 Billion|
|Num Shares||143 Million|
|Price-to-Earnings (P/E) Ratio||-51.48|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||77.27|
|Resistance 3 (R3)||76.87||75.26||76.66|
|Resistance 2 (R2)||75.26||74.32||75.46||76.46|
|Resistance 1 (R1)||74.43||73.75||74.85||74.83||76.25|
|Support 1 (S1)||71.99||71.88||72.41||72.39||70.97|
|Support 2 (S2)||70.38||71.31||70.58||70.76|
|Support 3 (S3)||69.55||70.38||70.56|
|Support 4 (S4)||69.95|